Telix Pharmaceuticals Limited’s Revenue Growth at a glance
Telix Pharmaceuticals Limited reports revenue growth of 55.8% for Dec 2024. The prior period recorded 213.9% (Dec 2023). Year over year the metric moved −158.1 pts (−73.9%). The rolling three-period average stands at 759.1%. Data last refreshed Dec 7, 2025, 2:49 AM.
Latest reading
55.8% · Dec 2024
YoY movement
−158.1 pts (−73.9%)
Rolling average
759.1%
Current Revenue Growth
55.8%
−158.1 pts
−73.9%
Rolling average
759.1%
Latest Value
55.8%
Dec 2024
YoY Change
−158.1 pts
Absolute
YoY Change %
−73.9%
Rate of change
3-Period Avg
759.1%
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s revenue growth stands at 55.8% for Dec 2024. Year-over-year, the metric shifted by −158.1 pts, translating into a −73.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How revenue growth shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports revenue growth of 55.8%. Evaluate revenue acceleration, seasonality, and long-term expansion for U.S. equities using annual growth data.
How to read revenue growth
Consistent double-digit revenue growth typically indicates demand strength and market share gains. Sharp decelerations may point to competitive or macro headwinds.
Balancing growth with profitability
Growth only creates value when paired with improving margins or cash generation. Pair revenue growth with profitability metrics to judge overall health.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s revenue growth profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current revenue growth?
As of Dec 2024, Telix Pharmaceuticals Limited reports revenue growth of 55.8%. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's revenue growth trending year over year?
Year-over-year, the figure shifts by −158.1 pts (−73.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does revenue growth matter for Telix Pharmaceuticals Limited?
Revenue growth measures the percentage change in top-line sales compared with the prior period. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's revenue growth above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 759.1%. Comparing the latest reading of 55.8% to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's revenue growth refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:49 AM and updates automatically every 24 hours, keeping your valuation inputs current.